- High-Yield Topic: Preeclampsia with severe features requires immediate maternal stabilization (antihypertensives and magnesium sulfate) followed by prompt delivery.
- Diagnostic Criteria: Blood pressure ≥160/110 mmHg, along with signs of end-organ damage (e.g., elevated liver enzymes, thrombocytopenia, visual changes, or renal insufficiency).
- First-line Antihypertensives: Intravenous labetalol, intravenous hydralazine, or immediate-release oral nifedipine.
- SMLE Strategy: Differentiate indications for vaginal delivery versus cesarean section. Vaginal delivery is typically preferred even in severe preeclampsia unless obstetric contraindications exist.
- Preparation Tool: Consolidate these algorithms utilizing the SMLEREVISE High-Yield Question Bank and validate your readiness with SMLEREVISE Grand Mocks.
Clinical Case
Vignette: A 32-year-old primigravida at 37 weeks and 2 days gestation presents to the obstetric emergency department complaining of a severe, unrelenting headache, blurred vision, and persistent right upper quadrant abdominal pain. Her prenatal course was previously unremarkable until two weeks ago when mild hypertension was noted. Today, her vital signs are: Temperature 37.1°C, Blood Pressure 165/115 mmHg, Heart Rate 92 bpm, and Respiratory Rate 18 breaths/min. Physical examination reveals 3+ pitting edema in the lower extremities and hyperreflexia with 2 beats of clonus bilaterally. Urinalysis reveals 3+ proteinuria. Fetal heart rate monitoring demonstrates a baseline of 140 bpm, moderate variability, and no late or variable decelerations. Laboratory results show a platelet count of 95,000/μL, AST 110 U/L, and serum creatinine 1.2 mg/dL. What is the most appropriate next step in the management of this patient?
Initial Approach: When tackling any obstetrics question on the SMLE, the very first step is to establish the gestational age and maternal-fetal stability. In this vignette, we have a term patient (≥37 weeks) presenting with classic signs of severe end-organ dysfunction. The differential diagnosis for hypertension in pregnancy revolves around timing and severity. Because her blood pressure is critically elevated (≥160/110 mmHg) and she is exhibiting neurological symptoms (headache, blurred vision, clonus) alongside hepatic (RUQ pain, elevated AST) and hematologic (thrombocytopenia) abnormalities, the diagnosis is definitively preeclampsia with severe features (or potentially evolving HELLP syndrome).
Differential Thinking: Our differential must distinguish between gestational hypertension (no proteinuria or severe features), mild preeclampsia (BP ≥140/90 but <160/110 with proteinuria but no severe features), and chronic hypertension (diagnosed prior to 20 weeks gestation). Given the immediate threat of eclamptic seizures and maternal stroke from hypertensive crisis, management must pivot to emergent maternal stabilization and expedited delivery. To succeed, candidates must apply strategies detailed in Mastering the SMLE: Expert Strategies and Test-Day Excellence, rapidly identifying "red flag" clinical markers before even glancing at the options.
Option-by-Option Analysis
A) Administer intravenous labetalol and magnesium sulfate, then proceed with induction of labor.
This is the correct option. The patient is experiencing severe preeclampsia at term. Immediate management requires lowering the blood pressure to prevent maternal cerebrovascular accident (using IV labetalol, IV hydralazine, or PO nifedipine) and initiating seizure prophylaxis (IV magnesium sulfate). Because she is at term (≥37 weeks) and the fetal heart tracing is reassuring, vaginal delivery via induction of labor is the safest and most appropriate definitive treatment.
B) Administer intravenous magnesium sulfate and perform an immediate cesarean delivery.
While magnesium sulfate is entirely appropriate, an immediate cesarean delivery is incorrect. Preeclampsia, even with severe features, is not an absolute indication for cesarean section unless there are specific maternal or fetal contraindications to labor (e.g., non-reassuring fetal heart tracing, placental abruption, or fetal malpresentation). Vaginal delivery carries lower maternal morbidity.
C) Prescribe oral methyldopa and discharge home with close outpatient follow-up.
This option is dangerously incorrect. The patient has severe features of preeclampsia and an impending risk of eclampsia or stroke. Outpatient management and a weak, slow-acting antihypertensive like methyldopa are contraindicated. Patients with severe features must be admitted, acutely stabilized, and delivered.
D) Administer intravenous dexamethasone to accelerate fetal lung maturity.
This option is incorrect due to the gestational age. Antenatal corticosteroids (such as dexamethasone or betamethasone) are indicated to accelerate fetal lung maturity only in pregnancies between 24 and 34 weeks of gestation (and sometimes late preterm up to 36 weeks and 6 days in specific scenarios). At 37 weeks and 2 days, the fetus is considered term, and lung maturity is already established.
E) Expectant management until 39 weeks gestation.
Expectant management is fundamentally incorrect for any patient with preeclampsia with severe features after 34 weeks of gestation. While mild gestational hypertension or preeclampsia without severe features might be expectantly managed until 37 weeks, the presence of severe features mandates delivery once the patient is past 34 weeks to prevent catastrophic maternal and fetal complications.
| Hypertensive Disorder | Diagnostic Criteria | Key Features / Associations | Primary SMLE Management Rule |
|---|---|---|---|
| Chronic Hypertension | BP ≥140/90 prior to 20 weeks gestation | Often underlying vascular disease; risk of superimposed preeclampsia. | Maintain BP <160/110; deliver at 38-39 weeks if uncomplicated. |
| Gestational Hypertension | BP ≥140/90 after 20 weeks; NO proteinuria | Asymptomatic usually; 10-50% progress to preeclampsia. | Expectant management; deliver at 37 weeks. |
| Preeclampsia (w/o severe features) | BP ≥140/90 after 20 weeks + Proteinuria (≥300mg/24h) | Endothelial dysfunction; placental ischemia. | Deliver at 37 weeks; monitor closely. |
| Preeclampsia with Severe Features | BP ≥160/110 OR end-organ damage (liver, brain, kidney) | High risk for eclamptic seizures, HELLP syndrome, stroke. | Stabilize with MgSO4 + Anti-HTN. Deliver immediately if ≥34 weeks. |
Correct Answer & Explanation
Correct Answer: A. The optimal management for this patient is to administer intravenous labetalol and magnesium sulfate, followed by induction of labor. Preeclampsia is driven by abnormal cytotrophoblast invasion of spiral arteries, leading to placental hypoperfusion. The ischemic placenta releases antiangiogenic factors (like sFlt-1) into the maternal circulation, causing widespread systemic endothelial dysfunction. This manifests clinically as hypertension, increased vascular permeability (edema, proteinuria), and end-organ ischemia. The ultimate "cure" is the delivery of the placenta.
The patient in the vignette is experiencing a hypertensive crisis (BP ≥160/110) which drastically increases the risk of maternal intracranial hemorrhage. Intravenous labetalol (a combined alpha and beta-blocker) is a first-line agent that acts rapidly to safely reduce pressure. Concurrently, her severe headache, hyperreflexia, and clonus indicate extreme central nervous system irritability, making her an immense risk for eclamptic seizures. Intravenous magnesium sulfate is the definitive agent for seizure prophylaxis in this setting. Because she is at term (≥ 37 weeks), delivery is strictly indicated. Since the fetal heart tracing is reassuring, a trial of labor via induction is preferred over major abdominal surgery (cesarean).
To consistently nail these complex obstetrics scenarios, understanding the rationale behind the guidelines is essential. Relying on outdated prep materials can compromise your score. We highly recommend utilizing the SMLEREVISE High-Yield Question Bank, which reflects the most current 2025/2026 clinical guidelines, ensuring you learn modern management algorithms. Integrating this robust tool into your routine, as outlined in How to Prepare for the SMLE: The Ultimate 2026 Study Plan and Strategy Guide, guarantees your clinical reasoning remains sharp. Scoring well on these high-weight sections heavily dictates your overall percentile, a concept deeply explored in our SMLE Score Distribution and Passing Rates: The Definitive 2026 Guide.
Sina AI Memory Pearl
To never miss a severe preeclampsia diagnosis on the SMLE, remember the mnemonic "BP HACKED". It summarizes the immediate severe features that upgrade standard preeclampsia to an obstetrical emergency requiring immediate stabilization and delivery (if >34 weeks):
Blood pressure ≥160/110 mmHg.
Pulmonary edema.
Headaches (severe, unremitting).
AST/ALT elevated (double normal).
Creatinine elevated (>1.1 mg/dL or doubling).
Killer right upper quadrant/epigastric pain.
Eyes (visual disturbances, scotomata).
Decreased platelets (< 100,000).
When any of these "hacked" parameters appear in an SMLE vignette, immediately look for an answer choice offering Magnesium Sulfate + IV Antihypertensives + Delivery. Lock this mnemonic into your memory using the SMLEREVISE High-Yield Notes (HYN), which leverages spaced repetition to ensure these facts remain instantly accessible on test day, long after you've completed your SMLEREVISE Grand Mocks.
References
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2020.
- Saudi Commission for Health Specialties (SCFHS). Obstetrics and Gynecology SMLE Blueprint Guidelines, 2025/2026 Updates.
- UpToDate: Preeclampsia: Clinical features and diagnosis. (Accessed 2025).
- World Health Organization (WHO) recommendations for prevention and treatment of pre-eclampsia and eclampsia.